You Can Now Get a COVID-19 Vaccine in China. That Might Not Be a Good Thing
Li Shurui didn’t hesitate. Faced with putting his life on hold indefinitely or the risk of catching COVID-19 by returning to university in the U.K., the 22-year-old business student decided to roll up his sleeve and receive an experimental coronavirus vaccine. Two injections of CoronaVac made by SinoVac (otherwise known as Beijing Kexing Bioproducts) cost 2,000 rmb ($300) at the private Taihe Hospital in the Chinese capital. The treatment still hasn’t passed final (Stage 3) clinical trials but is already being offered to the public on a first come, first served basis. Anyone can turn up, pay their money and get...
Source: TIME: Health - October 22, 2020 Category: Consumer Health News Authors: Charlie Campbell/ Shanghai Tags: Uncategorized China COVID-19 feature overnight Source Type: news

Coronavirus live news: Germany sees 10,000 daily cases for first time as France infections top 1m
Spain becomes first western European country to pass 1m cases;Rome among latest to bring in curfew;German health minister has Covid-19. Follow the latest updatesNumber of US states seeing record one-day deaths rises to sixSpain is first western European country to pass 1m cases300,000 excess US deaths recorded as Cathay Pacific cuts 5,900 jobsWomen aged 50-60 at greatest risk of ‘long Covid’, experts suggestSee all our coronavirus coverage5.06amBSTBritain on Thursday said it would partner with an Oxford-based firm to provide testing for the T-cell response of coronavirus vaccine candidates to try to assess thei...
Source: Guardian Unlimited Science - October 22, 2020 Category: Science Authors: Helen Sullivan Tags: Coronavirus World news US news Australia news UK news Science Infectious diseases Source Type: news

COVID-19 Vaccines Should Be Available to the General Public by April 2021, Health Officials Say
COVID-19 vaccines are projected to be available to the entire American public by April 2021, U.S. Department of Health and Human Services Secretary Alex Azar said at an Oct. 21 press briefing. That timeline is in keeping with estimates made by other public-health officials, but is among the strongest and most specific statements made about the widespread availability of a coronavirus vaccine in the U.S. Two vaccine candidates—those made by Pfizer and Moderna—are nearing the end of the clinical trial process, and the pharmaceutical companies are already building up sizable stockpiles. Assuming these (and possibl...
Source: TIME: Health - October 21, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

Africa: Covid-19 - Another Vaccine Proposed
[Cameroon Tribune] The jab manufactured by a drug producing company known as Pfizer is currently under clinical trials. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 20, 2020 Category: African Health Source Type: news

No Pfizer COVID - 19 Vaccine Expected Before Election
Company has reversed its previous claims that it would apply for the approval in October (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 20, 2020 Category: Respiratory Medicine Tags: Family Medicine, Gynecology, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Institutional, Source Type: news

Pfizer: The Pace of COVID-19 Vaccine Development Is Remarkable, Says Analyst
The recent coronavirus vaccine race has been fraught with setbacks. Both Astra Zeneca and Johnson & Johnson recently halted their... (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2020 Category: Consumer Health News Source Type: news

No Pfizer COVID-19 Vaccine Expected Before Election
MONDAY, Oct. 19, 2020 -- Pfizer will not apply for emergency authorization of its COVID-19 vaccine before the third week in November, the company's chief executive said in a statement posted to the Pfizer website on Friday. This is a reversal from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2020 Category: Pharmaceuticals Source Type: news

Pfizer Says Earliest COVID-19 Vaccine Application to US Regulators Would Be After Election Pfizer Says Earliest COVID-19 Vaccine Application to US Regulators Would Be After Election
Pfizer said on Friday it may file for US authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 19, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Pfizer Reportedly Manufactures ‘Several Hundred Thousand’ Covid-19 Vaccines Anticipating November Regulatory Approval
The vaccines are ready to be rolled out worldwide should regulators approve it. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 19, 2020 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Manufacturing /manufacturing Editors' Pick editors-pick Breaking breaking-news Coronavirus Source Type: news

Experimental coronavirus vaccines: When they will roll out, side effects and what it all means for you
In Ohio, Pfizer and its partner BioNTechSE, and Moderna —forerunners in the race to develop a vaccine — are conducting trials at... (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2020 Category: Consumer Health News Source Type: news

Zydus Cadila gets tentative USFDA nod for generic drug
The company has received tentative approval from the US Food and Drug Administration (USFDA) for the product which is the generic version of Pfizer's Xeljanz XR tablets, Zydus Cadila said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 19, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus vaccine: Pfizer CEO discusses COVID-19 vaccine by end of November possibly
Pfizer CEO Albert Bourla announced the company’s Covid-19 vaccine could be available by late November. Yahoo Finance’s Anjalee Khemlani... (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2020 Category: Consumer Health News Source Type: news

Pfizer says it will not have a coronavirus vaccine until late November, allaying fears of a rush for approval before Election Day
Pfizer chief executive Albert Bourla confirmed Friday the company will not file for regulatory authorization until the third week of November. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 16, 2020 Category: Consumer Health News Authors: Carolyn Y. Johnson Source Type: news

Pfizer board member Dr. Scott Gottlieb details likelihood of coronavirus vaccine in late November
Dr. Scott Gottlieb, former FDA commissioner and Pfizer board member, joins "Closing Bell" to discuss comments from Pfizer that a vaccine... (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2020 Category: Consumer Health News Source Type: news

Fauci Plays a Key Role in Deciding When Vaccine Studies Are Done Fauci Plays a Key Role in Deciding When Vaccine Studies Are Done
Dr Anthony Fauci will see data from government-funded vaccine trials before the FDA does. One caveat: Pfizer ’ s study, which is ahead of the others, isn't included in his purview.ProPublica (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 16, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

No Pfizer Coronavirus Vaccine Before Election
Even though Pfizer could have preliminary data about the vaccine's effectiveness by the end of October, gathering safety and manufacturing data would take until at least the third week of November, Dr. Albert Bourla said in the statement. (Source: WebMD Health)
Source: WebMD Health - October 16, 2020 Category: Consumer Health News Source Type: news

Coronavirus Vaccine: Pfizer Says It Won't Seek Authorization Before Mid-November
Friday ’s announcement represents a shift in tone for the company and its leader, who has repeatedly emphasized the month of October in interviews and public appearances. (Source: NYT Health)
Source: NYT Health - October 16, 2020 Category: Consumer Health News Authors: Katie Thomas and Noah Weiland Tags: your-feed-science Clinical Trials Vaccination and Immunization United States Politics and Government Presidential Election of 2020 Coronavirus (2019-nCoV) Food and Drug Administration Pfizer Inc Bourla, Albert Trump, Donald J Source Type: news

Pfizer: Mid-November earliest it can seek virus vaccine OK
Pfizer CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well (Source: ABC News: Health)
Source: ABC News: Health - October 16, 2020 Category: Consumer Health News Tags: Health Source Type: news

Pfizer Will Seek Emergency Approval For Covid-19 Vaccine In November, After Election
The U.S. Food and Drug Administration needs at least two months of safety data before authorizing emergency use of any experimental Covid-19 vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 16, 2020 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Breaking breaking-news Coronavirus Source Type: news

Pfizer eyes emergency use approval for vaccine in November
Pfizer said on Friday it would apply for emergency use in the U.S. of its Covid-19 vaccine candidate as soon as a safety milestone is... (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2020 Category: Consumer Health News Source Type: news

Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November
Drug giant Pfizer said it could be ready to apply for emergency-use authorization of its Covid-19 vaccine by late November, assuming it... (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2020 Category: Consumer Health News Source Type: news

Dow Futures Lower As Markets Remain Focused on Stimulus Hopes, COVID Infection Rates; September Retail Sales in Focus
Wall Street is looking to snap a three-day losing streak Friday after Pfizer CEO Albert Bourla said the company "may know whether or not... (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2020 Category: Consumer Health News Source Type: news

Pfizer gets green light for first Covid-19 vaccine trials for children
Pfizer's Covid-19 trials are well under way. Now, the Chesterfield-based drug company is planning to start testing its experimental coronavirus vaccine on children as young as 12. "I think it's a very necessary step. I'm glad to see that," said Dr. Rachel Charney. Charney is a pediatric emergency medicine physician at Cardinal Glennon Chil dren's Hospital. "We want to know if it is effective and equally safe in our younger population and so that's when we start introducing pediatric trials," Charney… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 15, 2020 Category: Health Management Authors: Robert Townsend - KSDK Source Type: news

Pfizer gets green light for first Covid-19 vaccine trials for children
Pfizer's Covid-19 trials are well under way. Now, the Chesterfield-based drug company is planning to start testing its experimental coronavirus vaccine on children as young as 12. "I think it's a very necessary step. I'm glad to see that," said Dr. Rachel Charney. Charney is a pediatric emergency medicine physician at Cardinal Glennon Chil dren's Hospital. "We want to know if it is effective and equally safe in our younger population and so that's when we start introducing pediatric trials," Charney… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 15, 2020 Category: Biotechnology Authors: Robert Townsend - KSDK Source Type: news

BioLife Solutions to use cold storage tech to store potential Covid-19 vaccine
BioLife Solutions announced Wednesday its newly acquired company, SciSafe, received a $2.7 million, two-year contract to use its cold chain management and storage tools for a potential Covid-19 vaccine. BioLife Solutions CEO Mike Rice did not name the pharmaceutical company the Bothell-based business is working with and developing a vaccine. Two U.S. companies — Massachusetts-based Moderna and New York-based Pfizer — are furthest along in development of a Covid-19 vaccine, both of which need … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 15, 2020 Category: Pharmaceuticals Authors: Megan Campbell Source Type: news

Pfizer's shot left fewer than half of participants with side effects
About 80% of adults aged 65 to 85 reported mild to moderate reactions after receiving Pfizer's first vaccine compared to 55% give the second jab, which caused no redness or swelling after either dose. (Source: the Mail online | Health)
Source: the Mail online | Health - October 14, 2020 Category: Consumer Health News Source Type: news

'Slim' chance that Oxford's coronavirus vaccine will be ready in 2020, jab chief says
Kate Bingham, chair of the UK's Vaccine Taskforce, said she hopes to see late-stage trial data for the Oxford and Pfizer jabs by the end of 2020. (Pictured: Ms Bingham receiving an experimental jab) (Source: the Mail online | Health)
Source: the Mail online | Health - October 14, 2020 Category: Consumer Health News Source Type: news

U.S. Government Asks Vaccine Makers To Hold Filing for Authorization Until They Have Enough Doses to Distribute
As the COVID-19 pandemic enters its 10th month, the pressure to develop an effective vaccine, or vaccines, continues to mount. Speaking at the Johns Hopkins University and University of Washington Vaccine Symposium online, Dr. Moncef Slaoui, scientific head of Operation Warp Speed—the government organization funding and supporting development and distribution of COVID-19 vaccines—provided the latest updates on when a vaccine (and how many doses) might be available in coming months. Perhaps most strikingly, Slaoui said that the government has told vaccine manufacturers not to seek authorization of their drugs fr...
Source: TIME: Health - October 7, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Exact Sciences and Pfizer Extend and Amend Cologuard(R) Promotion Agreement
Successful collaboration will continue to support Cologuard adoption through 2022 MADISON, Wis. and NEW YORK, Oct. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (Nasdaq: EXAS) and Pfizer Inc. (NYSE: PFE) today announced an e... Diagnostics, Oncology Exact Sciences, Pfizer, Cologuard, colorectal cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 7, 2020 Category: Pharmaceuticals Source Type: news

Trump funneled billions to Operation Warp Speed vaccine companies through defense contract management firm, completely bypassing regulators
(Natural News) The more than $6 billion that the Trump administration awarded to pharmaceutical giants Novavax, Pfizer, Sanofi, and Johnson & Johnson to develop vaccines for the Wuhan coronavirus (covid-19) cannot be publicly accounted for with transparency because it was first funneled through a defense contract management firm, we have learned. NPR, doing the type... (Source: NaturalNews.com)
Source: NaturalNews.com - October 7, 2020 Category: Consumer Health News Source Type: news

Coronavirus live updates: White House blocks FDA vaccine guidelines; EU reviewing Pfizer drug in real-time
The coronavirus has infected more than 35.5 million people globally as of Tuesday, killing at least 1.04 million people so far. (Source: Reuters: Health)
Source: Reuters: Health - October 6, 2020 Category: Consumer Health News Source Type: news

Report: Moderna and Pfizer Vaccine Trial Participants Report Serious Side Effects
Five patients across the two studies apparently experienced chills, fever, and intense headaches. (Source: Reuters: Health)
Source: Reuters: Health - October 6, 2020 Category: Consumer Health News Source Type: news

BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies' vaccine development program against COVID-19. The EMA's decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, (Source: World Pharma News)
Source: World Pharma News - October 6, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

EU fast-tracks process for Pfizer and BioNTech’s Covid-19 vaccine
German group says any accelerated regulatory approval would not dilute safety standards (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 6, 2020 Category: Pharmaceuticals Source Type: news

White House cited drug companies ’ objections in overruling FDA’s vaccine standards
Trump’s back-channel conversations with Pfizer raise concerns that the president and drug makers are working behind regulators’ backs. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2020 Category: Consumer Health News Source Type: news

EU reviewing Pfizer-BioNTech COVID-19 vaccine in real time
Pfizer and BioNTech said in a joint statement the start of the review is based on data from laboratory and animal testing, as well as early testing on humans, while continuing talks to submit data as it emerged. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2020 Category: Pharmaceuticals Source Type: news

Why You Can Be Confident That An Approved Coronavirus Vaccine Will Be Safe And Effective
Dr. Stephen Thomas, Chief of Infectious Diseases at SUNY Upstate Medical University, who ’s been involved in multiple vaccine trials and is leading a Pfizer Covid-19 trial, explains that while concerns about a Covid-19 vaccine are understandable, the development process is sound. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 2, 2020 Category: Pharmaceuticals Authors: Stephen Thomas, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Policy /policy Editors' Pick editors-pick Coronavirus Source Type: news

Up Close and Personal: A Life of Service - The Dr. Dirk Vander Mijnsbrugge Story
Sitting around the kitchen table, Dirk ’s family can’t help but talk about medicine. Dirk, his wife, all three of their children and their spouses are all doctors. With Dirk being the only one to go into industry, he was the target of much teasing. But not anymore. Here’s Dirk’s story.  The youngest son in a lower-middle class family, Dirk Vander Mijnsbrugge was raised to serve others. His parents modelled a life of service; his mom serving their family while his father served their country in the military.    Outside the family, his parents were deeply involved in social service an...
Source: EyeForPharma - October 2, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Pfizer chief hits out at politicisation of Covid-19 vaccine
Albert Bourla says discussion of timeline during presidential debate had confused public (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 1, 2020 Category: Pharmaceuticals Source Type: news

Internal Memo: Pfizer CEO Slams Politicization Of Vaccine Development During Presidential Debate
“I was disappointed that the prevention for a deadly disease was discussed in political terms rather than scientific facts,” CEO Albert Bourla said. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 1, 2020 Category: Pharmaceuticals Authors: Rachel Sandler, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Source Type: news

FDA Expands Polyarticular-Course JIA Indications for Tofacitinib FDA Expands Polyarticular-Course JIA Indications for Tofacitinib
The approval of tablet and oral solution formulations, announced this week by the drug's manufacturer Pfizer, marks the first Janus kinase inhibitor to be approved for the condition in the US.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 1, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

BOMBSHELL: Former Pfizer executive says covid-19 "pandemic is over," so-called "second wave" based on fraudulent testing
(Natural News) Despite claims by Anthony Fauci and others that Americans should brace for a “second wave” of the Wuhan coronavirus (covid-19), former Pfizer Chief Science Officer Dr. Mike Yeadon says this is nothing but fear-mongering based on junk science and fraud. A former vice president at the pharmaceutical giant, Dr. Yeadon claims that “almost... (Source: NaturalNews.com)
Source: NaturalNews.com - September 30, 2020 Category: Consumer Health News Source Type: news

All eyes are on Pfizer as Trump pushes for vaccine by October
In media appearances and talks with investors, Pfizer ’s chief executive nearly always mentions a word that is so politically perilous, most of his competitors shy away from it: October. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 30, 2020 Category: Pharmaceuticals Authors: Katie Thomas Source Type: news

Will Pfizer's Vaccine Be Ready in October? Here's Why That's Unlikely.
Despite slim chances that its vaccine will be ready by October, Pfizer has big incentives to hint that it might be. (Source: NYT Health)
Source: NYT Health - September 30, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Pfizer Inc Coronavirus (2019-nCoV) Vaccination and Immunization Bourla, Albert your-feed-science Clinical Trials Drugs (Pharmaceuticals) United States Politics and Government AstraZeneca PLC Food and Drug Administration Johnson & M Source Type: news

Pfizer CEO on the pressures of creating a covid-19 vaccine: ‘What is at stake is beyond imagination’
Albert Bourla discusses the progress, hopes and the politics of a possible vaccine this fall. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - September 29, 2020 Category: Consumer Health News Authors: KK Ottesen Source Type: news

U.S. FDA Approves Pfizer ’s Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
NEW YORK--(BUSINESS WIRE) September 28, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib) for the treatment of children and adolescents 2 years and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2020 Category: Drugs & Pharmacology Source Type: news

A Real Vaccine Before the Election? It'd Take a Miracle. A Real Vaccine Before the Election? It'd Take a Miracle.
There is a small chance that Pfizer's vaccine trial will yield results by Nov. 3. Here's everything that has to happen and how to tell a political stunt from a real vaccine.ProPublica (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 28, 2020 Category: Intensive Care Tags: Public Health & Prevention News Source Type: news

Novavax Enters Final Stage of Coronavirus Vaccine Trials
The Maryland company, which has never brought a vaccine to market, has started its Phase 3 trial in the United Kingdom, with plans to begin in the United States in October. (Source: NYT Health)
Source: NYT Health - September 24, 2020 Category: Consumer Health News Authors: Katie Thomas and Carl Zimmer Tags: Novavax Inc Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Johnson & Moderna Inc Pfizer Inc Research Influenza Drugs (Pharmaceuticals) Great Britain United States Source Type: news

Big Pharma abandons all remaining traces of reputable science with mad rush to release COVID-19 vaccines
(Natural News) Describing the approach of Pfizer in getting its “warp speed” Wuhan coronavirus (COVID-19) vaccine to market before anyone else, Eric Topol, the editor-in-chief of Medscape, used the words “Olympic record” to suggest that the process is being rushed with little regard for sound science. As the company competes with other drug giants like... (Source: NaturalNews.com)
Source: NaturalNews.com - September 24, 2020 Category: Consumer Health News Source Type: news